Free Trial
OTCMKTS:HLOSF

Healios K.K. Earnings Date & Estimates

Healios K.K. logo
$1.80 0.00 (0.00%)
As of 11/6/2026

Healios K.K. is estimated to report earnings on Thursday, November 12, 2026.

What Analysts Expect from Healios K.K.

Healios K.K. is expected to post earnings of -$0.0719 per share on revenue of $212 thousand.

Consensus Estimates

Consensus EPS
-$0.0719
Expected Revenue
$212 thousand

Prepare for the Earnings Call

Healios K.K. Earnings FAQ

Healios K.K. (OTCMKTS:HLOSF) is estimated to report earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Healios K.K. to post earnings of -$0.0719 per share for the quarter.

The consensus revenue estimate for Healios K.K. is $212 thousand for the quarter.

Healios K.K. Earnings Headlines

Healios K.K. (HLOSF) Set to Release Earnings on Thursday
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Healios K.K. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Healios K.K.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Healios K.K. and other key companies, straight to your email.

About Healios K.K.

Healios K.K. (OTCMKTS:HLOSF) is a Japanese biotechnology company focused on developing regenerative medicine and cell therapies. Its research draws on induced pluripotent stem cell (iPSC) technology and somatic stem cell platforms, with the goal of treating serious diseases that have limited treatment options.

The company’s development programs have included HLCM051, a stem cell therapy investigated for conditions such as acute ischemic stroke and acute respiratory distress syndrome, as well as iPSC-based approaches for diseases including retinal disorders. These are investigational programs, not descriptions of commercially available treatments.

Founded in 2011 and headquartered in Tokyo, Healios has worked with academic and industry partners in Japan and internationally. The company was founded by Hardy Kagimoto, who has served as its chief executive.

View Healios K.K. Profile